A Phase 1, Open-label, Single Arm Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Saroglitazar Magnesium Dosed on Alternate Days in Subjects Having Moderate Hepatic Impairment with Cirrhosis Due to Cholestatic Liver Disease
Latest Information Update: 13 Jun 2025
At a glance
- Drugs Saroglitazar (Primary)
- Indications Biliary cirrhosis; Liver disorders
- Focus Pharmacokinetics
- Sponsors Zydus Pharmaceuticals (USA)
Most Recent Events
- 29 May 2025 Planned primary completion date changed from 31 Aug 2025 to 31 May 2025.
- 19 Feb 2025 New trial record